Tim Ruff, Senior Vice President of Business Development and Corporate Strategy, Molex, said: “This strategic acquisition broadens the scope of our integrated medical solution offerings and significantly strengthens our medical device design, manufacturing, and test capabilities.
“ProTek Medical Ltd excels in clean room injection moulding and assembly, has an extensive metrology lab, and the quality and regulatory expertise that is critical to global medical device manufacturers.”
ProTek Medical Ltd will continue to operate as a subsidiary of Molex Ireland Holdings, B.V. Founded in 1995, ProTek Medical Ltd has a portfolio of applications that include cardiac rhythm management components, infusion finished devices, and vascular delivery devices.
Within the global medical industry, ProTek Medical Ltd is recognised for its design, engineering, manufacturing, finished assembly and testing of critical medical devices.
This acquisition also expands the Molex medical footprint to Ireland, which has a large concentration of successful medical device companies.
“The acquisition presents new opportunities to achieve faster growth by expanding into new regions and healthcare market segments,” added Frank Boyle, Founder and CEO, ProTek Medical Ltd.
“Our customers will benefit from the unique capabilities, electromechanical technologies and global supply chain that Molex offers. We will now have the ability to easily scale to serve high mix, low and high volume production requirements to SME and large medical device OEM customers worldwide.”